Literature DB >> 11176968

Missense CACNA1A mutation causing episodic ataxia type 2.

C Denier1, A Ducros, A Durr, B Eymard, B Chassande, E Tournier-Lasserve.   

Abstract

OBJECTIVES: To characterize the nature of CACNA1A mutation in a previously unreported family with episodic ataxia type 2 (EA2) and to better delineate EA2 clinical features.
BACKGROUND: Episodic ataxia type 2 is an autosomal dominant disorder characterized by the recurrence of acetazolamide-responsive spells of cerebellar ataxia, usually starting during childhood or adolescence. The mutated gene, CACNA1A, is located on chromosome 19 and encodes the alpha1A subunit voltage-dependent calcium channel. So far, most CACNA1A mutations detected in patients with EA2 have led to a truncated CACNA1A protein, whereas missense mutations cause familial hemiplegic migraine.
METHODS: All 47 exons of CACNA1A were screened by a combination of single-strand conformer polymorphism and sequencing analysis.
RESULTS: A CACNA1A missense mutation, Glu 1757 Lys, was identified. It was absent in 200 control chromosomes. It is predicted to result in an amino acid substitution at a highly phylogenetically conserved position, within a domain that plays a major role in the function of the channel.
CONCLUSIONS: The Glu 1757 Lys missense mutation is likely to be pathogenic, causing episodic ataxia within a family whose phenotype is indistinguishable from EA2 except for a slightly later age of onset. These data strongly suggest that additional work is needed to fully establish genotype/phenotype correlations for CACNA1A mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176968     DOI: 10.1001/archneur.58.2.292

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

Review 1.  In vivo analysis of voltage-dependent calcium channels.

Authors:  Ling Liu; Theresa A Zwingman; Colin F Fletcher
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

2.  Long-term improvement of paroxysmal dystonic choreathetosis with acetazolamide.

Authors:  Veronique Michel; Florence Riant; Elisabeth Tournier-Lasserve; Dominique Guehl; Alain Lagueny; Bernard Bioulac; Pierre Burbaud
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

Review 3.  Migraine genetics: an update.

Authors:  J Haan; E E Kors; Kaate R J Vanmolkot; Arn M J M van den Maagdenberg; Rune R Frants; M D Ferrari
Journal:  Curr Pain Headache Rep       Date:  2005-06

4.  Dominant-negative suppression of Cav2.1 currents by alpha(1)2.1 truncations requires the conserved interaction domain for beta subunits.

Authors:  Robert S Raike; Holly B Kordasiewicz; Randall M Thompson; Christopher M Gomez
Journal:  Mol Cell Neurosci       Date:  2006-12-11       Impact factor: 4.314

Review 5.  The cerebellum and migraine.

Authors:  Maurice Vincent; Nouchine Hadjikhani
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

Review 6.  Homeostatic compensation maintains Ca2+ signaling functions in Purkinje neurons in the leaner mutant mouse.

Authors:  David Murchison; Leonard S Dove; Louise C Abbott; William H Griffith
Journal:  Cerebellum       Date:  2002-04       Impact factor: 3.847

7.  Novel splice site CACNA1A mutation causing episodic ataxia type 2.

Authors:  M A Kaunisto; H Harno; M Kallela; H Somer; R Sallinen; E Hämäläinen; P J Miettinen; J Vesa; A Orpana; A Palotie; M Färkkilä; M Wessman
Journal:  Neurogenetics       Date:  2003-10-07       Impact factor: 2.660

Review 8.  Calcium channels and channelopathies of the central nervous system.

Authors:  Daniela Pietrobon
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 9.  Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.

Authors:  Wolfgang Nachbauer; Michael Nocker; Elfriede Karner; Iva Stankovic; Iris Unterberger; Andreas Eigentler; Rainer Schneider; Werner Poewe; Margarete Delazer; Sylvia Boesch
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

Review 10.  Episodic ataxia type 1: a neuronal potassium channelopathy.

Authors:  Sanjeev Rajakulendran; Stephanie Schorge; Dimitri M Kullmann; Michael G Hanna
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.